Conversely, the administration of CAMK inhibitor (KN93) impeded either glycolysis or GLUT1 in naïve T cells from MRL/lpr mice and isolated CD4+ T cells from patients with SLE, consolidating the metabolic modulation property of CAMK (Table 1) (114). Here, CD4 is linked to systemic lupus erythematosus.